Xeris Biopharma Holdings (XERS) Revenue Growth (1y) (2021 - 2026)
Xeris Biopharma Holdings (XERS) Revenue Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 2.34% |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 2.91% |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -11.85% |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | -1.62% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 7.85% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 42.25% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 14.92% |
| 10 | Xeris Biopharma Holdings | 1.41 Bn | 1.30 Bn | 72.55 Mn | 38.27% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 38.27% |
| Dec 31, 2025 | 42.78% |
| Sep 30, 2025 | 37.06% |
| Jun 30, 2025 | 48.84% |
| Mar 31, 2025 | 47.94% |
| Dec 31, 2024 | 35.39% |
| Sep 30, 2024 | 12.31% |
| Jun 30, 2024 | 26.46% |
| Mar 31, 2024 | 22.42% |
| Dec 31, 2023 | 33.93% |
| Sep 30, 2023 | 62.56% |
| Jun 30, 2023 | 50.19% |
| Mar 31, 2023 | 50.39% |
| Dec 31, 2022 | 54.67% |
| Sep 30, 2022 | 168.76% |
| Jun 30, 2022 | 184.15% |
| Mar 31, 2022 | 169.35% |
| Dec 31, 2021 | 203.74% |
| Sep 30, 2021 | 17.66% |